Page 146 WHO - Guidelines on the pharmacological treatment of persisting pain in children with medical illness

(Singapore), Roger Chou (USA), Jacqui Clinch (United Kingdom), Mark Connelly (USA), Hadeel Fakhri
Ahmad Daghash (Saudi Arabia), Silvia Maria de Macedo Barbosa (Brazil), C.R. Beena Devi (Malaysia),
Christopher Drasbek (WHO), Verna Edwards (Jamaica), Ivanhoe C. Escartin (the Philippines), Eunice A1
Garanganga (Zimbabwe), Raúl González (WHO), Ruth Guinsburg (Brazil), Susan M. Huff (USA), Nancy
Hutton (USA), Jack G.M. Jagwe (Uganda), Khaliah Johnson (USA), Rut Kiman (Argentina), Benjamin H.
Lee (USA), Stuart M. MacLeod (Canada), Loeto Mazhani (Botswana), Doris Mesia Vela (Belgium), Faith
Mwangi-Powell (Uganda), Kathleen Neville (USA), Daniel Orbach (France), Vadim Pogonet (Republic of
Moldova), M.R. Rajagopal (India), Shalini Sri Ranganathan (Sri Lanka), Karen Ryan (USA), Nevil Sethna
(USA), Rose Shija (WHO), Hardo Sorgatz (Germany), Sri Suryawati (Indonesia), Jean Claude K. Tayari
(Rwanda), Leon Tshilolo (the Democratic Republic of the Congo), Gary A. Walco (USA), Roberto Daniel A2
Wenk (Argentina), Phil Wiffen (United Kingdom), Chantal Wood (France), Boris Zernikow (Germany).

WHO consultants
Shalini Jayasekar (Switzerland), Rita Kabra (Switzerland), Neeta Kumar (Kenya) and Bee Wee (Senior
Lecturer in Palliative Medicine, Oxford University, United Kingdom).
Methodologist: Phil Wiffen (Director of Training, UK Cochrane Centre, Oxford, United Kingdom).
Pharmacological profiles initial drafts: Noel Cranswick, Brian Lilley, Leith Lilley, Christine Plover
(all: The Royal Children’s Hospital, Melbourne, Australia.) A3
Reviewers: Adrian Dabscheck , Rob McDougall (both: The Royal Children’s Hospital, Melbourne,
Australia).
Editors: Diana Hopkins (Switzerland), Rhona McDonalds (United Kingdom), Dorothy van Schooneveld
(France).
Design and lay-out: Paprika (France).

These guidelines were also made possible thanks to the support of WHO Staff Members André Buell, A4
Anna Colin, Pamela Drameh, Eric Georget, Suzanne Hill, Hans Hogerzeil, Kathleen Hurst, Evelyn Jiguet,
Eva Kaddu, Joanna McMahon, Clive Ondari, Tone Skaug and the WHO Guidelines Review Committee’s
Secretariat.

A7.3 Declaration of interest and management of

potential conflict of interest A5

All consultants, experts and contributors involved in the development of the guidelines were requested
to declare any conflicts of interest. The management of conflicts of interest was a key task throughout
the process, with particular attention being paid to the appraisal of evidence, the formulation of
recommendations and the external peer review process of the drafted guidelines.
A6
Declarations of interest by members of the Guidelines Development Group
Rae Bell declared that as a member of the editorial board of Smertefokus, the Pfizer pain publication,
5
she receives Norwegian kroner (NOR) 12 000–16 000 per year. She declared receiving travel support
from Pfizer. She also declared agreeing to receive an honorarium from the company Grünenthal for
participating in meetings of the Nordic Expert Group on tapentadol. She declared to be technical adviser
for pregabalin, marketed by Pfizer, in Norway. Tapentadol and pregabalin were not included among the
medicines considered for clinical recommendations in these guidelines. A7

5 US$ 1 = NOK 5.75 (November 2011).

143 <